|Bid||17.30 x 3000|
|Ask||17.78 x 1000|
|Day's Range||17.01 - 17.78|
|52 Week Range||15.50 - 25.77|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||34.84|
|Earnings Date||Feb 08, 2022 - Feb 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.77|
Investment company Resonant Capital Advisors, LLC (Current Portfolio) buys Marqeta Inc, Vanguard Tax-Exempt Bond ETF, iShares National Muni Bond ETF, Apple Inc, Amazon.com Inc, sells Xilinx Inc, Biogen Inc, Citrix Systems Inc, Exelixis Inc, Citigroup Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Resonant Capital Advisors, LLC.
For more than a decade, growth stocks have been the talk of Wall Street. Since value stocks are profitable and time-tested, they're the perfect place for patient investors to put their money to work. Below are five value stocks that could make you richer in 2022.
ALAMEDA, Calif., January 18, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced results for cabozantinib (CABOMETYX®) in combination with immunotherapies in patients with advanced colorectal cancer, including encouraging data from cohort 16 of the phase 1b COSMIC-021 trial of cabozantinib in combination with atezolizumab in patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine-containing chemotherapy. Results from cohort 2 of the phase 2 CAMILLA trial of c